In our study, AML outcomes were similar to those of AML-NK, despite 69.2% being classified as AML-MR, while in MDS, concomitant somatic DDX41 variants were associated with a trend toward better survival. The gene discussed is DDX41; the disease is myelodysplastic syndrome.